vs
Orthofix Medical Inc.（OFIX）与Priority Technology Holdings, Inc.（PRTH）财务数据对比。点击上方公司名可切换其他公司
Priority Technology Holdings, Inc.的季度营收约是Orthofix Medical Inc.的1.1倍（$247.1M vs $219.9M），Priority Technology Holdings, Inc.净利率更高（3.6% vs -1.0%，领先4.6%），Priority Technology Holdings, Inc.同比增速更快（8.8% vs 2.0%），Priority Technology Holdings, Inc.自由现金流更多（$30.9M vs $16.8M），过去两年Priority Technology Holdings, Inc.的营收复合增速更高（9.6% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Priority Technology Holdings, Inc.是一家聚焦信息技术领域的企业，业务围绕计算机、通信系统等相关信息设备展开，涵盖信息的创建、处理、存储、检索与传输等相关信息技术应用服务，依托计算机科学与工程技术支撑业务开展。
OFIX vs PRTH — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $247.1M |
| 净利润 | $-2.2M | $8.9M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 13.6% |
| 净利率 | -1.0% | 3.6% |
| 营收同比 | 2.0% | 8.8% |
| 净利润同比 | 92.4% | 23.9% |
| 每股收益（稀释后） | $-0.05 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $219.9M | $247.1M | ||
| Q3 25 | $205.6M | $241.4M | ||
| Q2 25 | $203.1M | $239.8M | ||
| Q1 25 | $193.6M | $224.6M | ||
| Q4 24 | $215.7M | $227.1M | ||
| Q3 24 | $196.6M | $227.0M | ||
| Q2 24 | $198.6M | $219.9M | ||
| Q1 24 | $188.6M | $205.7M |
| Q4 25 | $-2.2M | $8.9M | ||
| Q3 25 | $-22.8M | $27.6M | ||
| Q2 25 | $-14.1M | $10.9M | ||
| Q1 25 | $-53.1M | $8.3M | ||
| Q4 24 | $-29.1M | $7.2M | ||
| Q3 24 | $-27.4M | $10.6M | ||
| Q2 24 | $-33.4M | $994.0K | ||
| Q1 24 | $-36.0M | $5.2M |
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
| Q4 25 | 0.2% | 13.6% | ||
| Q3 25 | -8.3% | 15.6% | ||
| Q2 25 | -7.9% | 15.6% | ||
| Q1 25 | -25.2% | 14.5% | ||
| Q4 24 | -5.3% | 15.0% | ||
| Q3 24 | -9.6% | 16.8% | ||
| Q2 24 | -12.5% | 15.1% | ||
| Q1 24 | -15.6% | 13.6% |
| Q4 25 | -1.0% | 3.6% | ||
| Q3 25 | -11.1% | 11.4% | ||
| Q2 25 | -6.9% | 4.5% | ||
| Q1 25 | -27.4% | 3.7% | ||
| Q4 24 | -13.5% | 3.2% | ||
| Q3 24 | -13.9% | 4.7% | ||
| Q2 24 | -16.8% | 0.5% | ||
| Q1 24 | -19.1% | 2.5% |
| Q4 25 | $-0.05 | $0.10 | ||
| Q3 25 | $-0.57 | $0.34 | ||
| Q2 25 | $-0.36 | $0.14 | ||
| Q1 25 | $-1.35 | $0.10 | ||
| Q4 24 | $-0.76 | $-0.05 | ||
| Q3 24 | $-0.71 | $0.07 | ||
| Q2 24 | $-0.88 | $-0.23 | ||
| Q1 24 | $-0.95 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $77.2M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $450.0M | $-100.4M |
| 总资产 | $850.6M | $2.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $82.0M | $77.2M | ||
| Q3 25 | $62.9M | $57.0M | ||
| Q2 25 | $65.6M | $50.6M | ||
| Q1 25 | $58.0M | $47.6M | ||
| Q4 24 | $83.2M | $58.6M | ||
| Q3 24 | $30.1M | $41.1M | ||
| Q2 24 | $26.4M | $34.6M | ||
| Q1 24 | $27.0M | $34.3M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | $157.2M | $997.5M | ||
| Q2 25 | $157.0M | $917.0M | ||
| Q1 25 | $156.9M | $918.9M | ||
| Q4 24 | $157.0M | $920.9M | ||
| Q3 24 | $118.5M | $808.1M | ||
| Q2 24 | $118.0M | $809.0M | ||
| Q1 24 | $118.2M | $631.4M |
| Q4 25 | $450.0M | $-100.4M | ||
| Q3 25 | $442.5M | $-110.3M | ||
| Q2 25 | $458.3M | $-146.1M | ||
| Q1 25 | $458.3M | $-158.3M | ||
| Q4 24 | $503.1M | $-166.8M | ||
| Q3 24 | $525.9M | $-165.8M | ||
| Q2 24 | $546.0M | $-172.1M | ||
| Q1 24 | $570.3M | $-159.9M |
| Q4 25 | $850.6M | $2.4B | ||
| Q3 25 | $832.6M | $2.2B | ||
| Q2 25 | $837.2M | $2.0B | ||
| Q1 25 | $823.1M | $1.9B | ||
| Q4 24 | $893.3M | $1.8B | ||
| Q3 24 | $867.9M | $1.8B | ||
| Q2 24 | $882.0M | $1.7B | ||
| Q1 24 | $906.0M | $1.6B |
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $36.8M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $30.9M |
| 自由现金流率自由现金流/营收 | 7.6% | 12.5% |
| 资本支出强度资本支出/营收 | 4.9% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 4.12× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $75.1M |
8季度趋势，按日历期对齐
| Q4 25 | $27.7M | $36.8M | ||
| Q3 25 | $12.4M | $36.1M | ||
| Q2 25 | $11.6M | $17.1M | ||
| Q1 25 | $-18.4M | $10.0M | ||
| Q4 24 | $23.7M | $23.8M | ||
| Q3 24 | $11.7M | $19.8M | ||
| Q2 24 | $9.0M | $28.7M | ||
| Q1 24 | $-18.6M | $13.3M |
| Q4 25 | $16.8M | $30.9M | ||
| Q3 25 | $2.5M | $30.1M | ||
| Q2 25 | $4.5M | $9.2M | ||
| Q1 25 | $-25.1M | $4.9M | ||
| Q4 24 | $15.2M | $19.1M | ||
| Q3 24 | $6.3M | $14.5M | ||
| Q2 24 | $-360.0K | $23.6M | ||
| Q1 24 | $-29.1M | $6.7M |
| Q4 25 | 7.6% | 12.5% | ||
| Q3 25 | 1.2% | 12.5% | ||
| Q2 25 | 2.2% | 3.8% | ||
| Q1 25 | -13.0% | 2.2% | ||
| Q4 24 | 7.0% | 8.4% | ||
| Q3 24 | 3.2% | 6.4% | ||
| Q2 24 | -0.2% | 10.7% | ||
| Q1 24 | -15.4% | 3.3% |
| Q4 25 | 4.9% | 2.4% | ||
| Q3 25 | 4.8% | 2.5% | ||
| Q2 25 | 3.5% | 3.3% | ||
| Q1 25 | 3.5% | 2.3% | ||
| Q4 24 | 4.0% | 2.0% | ||
| Q3 24 | 2.7% | 2.3% | ||
| Q2 24 | 4.7% | 2.3% | ||
| Q1 24 | 5.6% | 3.2% |
| Q4 25 | — | 4.12× | ||
| Q3 25 | — | 1.31× | ||
| Q2 25 | — | 1.57× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 3.29× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 28.87× | ||
| Q1 24 | — | 2.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PRTH
暂无分部数据
